Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA

Court blesses combination of statements and disclosures that must accompany Vascepa promotions in a ruling that rejects FDA's narrow interpretation of 2012 Caronia case.